2022 American Transplant Congress
Detection of Early Graft Injury After Liver Transplantation with Blood-Bile Ratio of Tacrolimus: The TUBE Trial
*Purpose: The aim of the“Tacrolimus in Bile”(TUBE)Trial is the creation of a laboratory parameter for the early detection of hepatic injury after liver transplant.*Methods: TUBE…2022 American Transplant Congress
Effect of Schisandra Sphenanthera Extract on Pharmacokinetics of Tacrolimus in Pediatric Renal Transplant Recipients
*Purpose: Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent in adult renal transplant recipients, while its effect in pediatric recipients remains unclear. The…2022 American Transplant Congress
Effect of Dual Inhibition of DPP4 and SGLT2 on Tacrolimus-Induced Diabetes Mellitus and Nephrotoxicity in Rat Model
Seoul St.Mary's Hospital, Seoul, Korea, Republic of
*Purpose: Sodium/glucose co-transporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase IV inhibitor (DPP4i) are popular anti-diabetic drugs in type II diabetes mellitus (DM), but their use in…2022 American Transplant Congress
Comparison of Immediate-Release Tacrolimus to Envarsus XR on the Development of Donor Specific Antibodies in Kidney Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Major causes of de novo development of donor specific antibodies (DSA) after kidney transplant include medication noncompliance and immunosuppression minimization or elimination that may…2022 American Transplant Congress
Implementing Clinical Decision Support Tools for Immunosuppressant Drug-Drug Interactions to Prevent Graft Failure
1MAPMG, Mc Lean, VA, 2Kaiser Permanente, Silver Spring, MD, 3MAPMG, Rockville, MA
*Purpose: Immunosuppressant drug-drug interactions can result in immunosuppressant toxicity or subtherapeutic levels causing rejection. If not identified and managed appropriately, these interactions may result in…2022 American Transplant Congress
An Interim Report on a Prospective Randomized Trial of Extended-Release Tacrolimus in Liver Transplantation with Anti-Thymocyte Induction in a Steroid Free Protocol
*Purpose: Our study hypothesis was that once daily dosing of extended-release tacrolimus (ERT) would be a safe and effective immunosuppression (IS) with the potential to…2022 American Transplant Congress
Evaluation of Compliance and Efficacy with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Tacrolimus in Kidney Transplant Recipients
*Purpose: The purpose of this study is to evaluate compliance and efficacy of The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype guided tacrolimus…2022 American Transplant Congress
Engineered IL-2 Plus Calcineurin Inhibitor Synergistically Expands Regulatory T Cells Transduced with Engineered IL-2 Receptor and Facilitates Establishment of Transplantation Tolerance
*Purpose: Clinical trials for regulatory T cell (Treg) therapy in organ transplant has shown promising results. However, it is still under the debate which drugs…2022 American Transplant Congress
Differences of Fk-Binding Protein 12 and P-Glycoprotein Explain the Differences in the Intracellular Tacrolimus Concentration of T Lymphocytes and Monocytes
Erasmus MC, Rotterdam, Netherlands
*Purpose: Little is known about the pharmacokinetics of intracellular tacrolimus, particularly in T lymphocytes and monocytes. We demonstrated a significantly lower intracellular tacrolimus concentration in…2022 American Transplant Congress
NecroX-7 Ameliorate FK506-Induced Nephrotoxicity in LLC-PK1 Cells (Pig Kidney Epithelial Cells)
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…
- 1
- 2
- 3
- …
- 14
- Next Page »